Global COVID-19 Vaccine Inequity: Failures in the First Year of Distribution and Potential Solutions for the Future

Abstract

Within the first year of distribution of vaccines against COVID-19, high-income countries (HICs) have achieved vaccination rates of 75-80%, whilst low-income countries (LICs) vaccinated <10%. This disparity in access has been one of the greatest failures of international cooperation during the SARS-CoV-2 pandemic. Global COVID-19 vaccine inequity affects us all, with ongoing risk of new variants emerging until global herd immunity is strengthened. The current model of global vaccine distribution is based on financial competition for limited vaccine supplies, resulting in HICs getting first access to vaccines, with LICs being forced to rely on voluntary donations through schemes like COVAX. Pharmaceutical companies own the intellectual property (IP) rights for COVID-19 vaccines, allowing them to control manufacturing, distribution, and pricing. However, the pharmaceutical industry did not develop these vaccines alone, with billions of dollars of public funding being instrumental in their discovery and development. Solutions to enable global equitable access already exist. The next step in scale up of manufacture and distribution worldwide is equitable knowledge sharing and technology transfer. The World Health Organization centralized technology transfer hub would facilitate international cooperation. Investments made into developing this infrastructure benefit the COVID-19 response whilst promoting future pandemic preparedness. Whilst globally there is majority support for waivers of IP to facilitate this next step, key opponents blocking this move include the UK and other European countries which host large domestic pharmaceutical industries. A nationalistic approach is not effective during a global pandemic. International cooperation is essential to achieve global goals against COVID-19.

Effectiveness of COVID-19 Vaccination in Preventing All-Cause Mortality among Adults during the Third Wave of the Epidemic in Hungary: Nationwide Retrospective Cohort Study

“…This is mainly because of the limited coverage of vaccination. The availability of vaccines against COVID-19 are limited only in low-income countries nowadays (lower than 20% of people have received at least one dose), while the unfavorable coverage of the developed countries can be explained mainly by vaccine hesitancy [ 4 , 5 ]. The acceptance of vaccination is primarily explained by the lack of and/or incorrect knowledge about the COVID-19 pandemic and the effectiveness of the vaccine.…”

Repurposed drugs and their combinations prevent morbidity-inducing dermonecrosis caused by diverse cytotoxic snake venoms

“…Further, evidence of inhibitory potential against C. atrox , a North American pit viper species, may enable a strategy for the future global translation of drug combination therapies by leveraging one of the few financially viable markets available for snakebite. Such an approach must, however, ensure that a robust access plan for LMIC communities is developed in parallel to avoid potential future distribution pitfalls, like those recently reported around the inequitable distribution of COVID vaccines 69,70 .…”

Editorial: Food Policy Environments: Discursive Effects, Material Consequences

“…The world continues to struggle with COVID-19. Workplaces in the food industry remain high-risk sites (Fabreau et al, 2022;Marks, 2022), and access to vaccines and treatments remains limited in many parts of the world (Pilkington et al, 2022). The pandemic has enhanced existing inequalities, and marginalized populations have been disproportionately affected by the crisis (Tai et al, 2021;Public Health Agency of Canada, 2022).…”